The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antisense Oligonucleotide (ASO) Therapeutics Market Research Report 2024
Synopsis
Market Analysis and Insights: Global Antisense Oligonucleotide (ASO) Therapeutics Market
The global Antisense Oligonucleotide (ASO) Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Pulmonary Delivery accounting for % of the Antisense Oligonucleotide (ASO) Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Genetic Disorders segment is altered to an % CAGR throughout this forecast period.
China Antisense Oligonucleotide (ASO) Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Antisense Oligonucleotide (ASO) Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antisense Oligonucleotide (ASO) Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense Oligonucleotide (ASO) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense Oligonucleotide (ASO) Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense Oligonucleotide (ASO) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense Oligonucleotide (ASO) Therapeutics market.
Global Antisense Oligonucleotide (ASO) Therapeutics Scope and Market Size
Antisense Oligonucleotide (ASO) Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antisense Oligonucleotide (ASO) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Topical Delivery
Others
Segment by Application
Genetic Disorders
Neurological Disorders
Oncological Disorders
Metabolic Disorders
Ophthalmic Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Ionis Pharmaceuticals, Inc
Sarpeta Therapeutics Inc.
Biogen Inc
Alnylam Pharmaceuticals, Inc
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
GlaxoSmithKline PLC
Geron Corporation (Geron)
Market Analysis and Insights: Global Antisense Oligonucleotide (ASO) Therapeutics Market
The global Antisense Oligonucleotide (ASO) Therapeutics market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Pulmonary Delivery accounting for % of the Antisense Oligonucleotide (ASO) Therapeutics global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Genetic Disorders segment is altered to an % CAGR throughout this forecast period.
China Antisense Oligonucleotide (ASO) Therapeutics market size is valued at US$ million in 2021, while the North America and Europe Antisense Oligonucleotide (ASO) Therapeutics are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Antisense Oligonucleotide (ASO) Therapeutics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Antisense Oligonucleotide (ASO) Therapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Antisense Oligonucleotide (ASO) Therapeutics market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Antisense Oligonucleotide (ASO) Therapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Antisense Oligonucleotide (ASO) Therapeutics market.
Global Antisense Oligonucleotide (ASO) Therapeutics Scope and Market Size
Antisense Oligonucleotide (ASO) Therapeutics market is segmented by players, region (country), by Type and by Application. Players, stakeholders, and other participants in the global Antisense Oligonucleotide (ASO) Therapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2017-2028.
Segment by Type
Pulmonary Delivery
Intravenous Injections
Intradermal Injections
Intraperitoneal Injections
Topical Delivery
Others
Segment by Application
Genetic Disorders
Neurological Disorders
Oncological Disorders
Metabolic Disorders
Ophthalmic Disorders
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
By Company
Ionis Pharmaceuticals, Inc
Sarpeta Therapeutics Inc.
Biogen Inc
Alnylam Pharmaceuticals, Inc
Antisense Therapeutics Limited
Arrowhead Pharmaceuticals Inc.
Enzon Pharmaceuticals, Inc.
Bio-Path Holdings, Inc.
GlaxoSmithKline PLC
Geron Corporation (Geron)
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type: 2017 VS 2021 VS 2028
1.2.2 Pulmonary Delivery
1.2.3 Intravenous Injections
1.2.4 Intradermal Injections
1.2.5 Intraperitoneal Injections
1.2.6 Topical Delivery
1.2.7 Others
1.3 Market by Application
1.3.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application: 2017 VS 2021 VS 2028
1.3.2 Genetic Disorders
1.3.3 Neurological Disorders
1.3.4 Oncological Disorders
1.3.5 Metabolic Disorders
1.3.6 Ophthalmic Disorders
1.3.7 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Perspective (2017-2028)
2.2 Antisense Oligonucleotide (ASO) Therapeutics Growth Trends by Region
2.2.1 Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Region (2017-2022)
2.2.3 Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2023-2028)
2.3 Antisense Oligonucleotide (ASO) Therapeutics Market Dynamics
2.3.1 Antisense Oligonucleotide (ASO) Therapeutics Industry Trends
2.3.2 Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
2.3.3 Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
2.3.4 Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue
3.1.1 Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Revenue (2017-2022)
3.1.2 Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Players (2017-2022)
3.2 Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Antisense Oligonucleotide (ASO) Therapeutics Revenue
3.4 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio
3.4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2021
3.5 Antisense Oligonucleotide (ASO) Therapeutics Key Players Head office and Area Served
3.6 Key Players Antisense Oligonucleotide (ASO) Therapeutics Product Solution and Service
3.7 Date of Enter into Antisense Oligonucleotide (ASO) Therapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Type
4.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Type (2017-2022)
4.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2023-2028)
5 Antisense Oligonucleotide (ASO) Therapeutics Breakdown Data by Application
5.1 Global Antisense Oligonucleotide (ASO) Therapeutics Historic Market Size by Application (2017-2022)
5.2 Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
6.2 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
6.3 North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
6.4 United States
6.5 Canada
7 Europe
7.1 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
7.2 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
7.3 Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
7.4 Germany
7.5 France
7.6 U.K.
7.7 Italy
7.8 Russia
7.9 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
8.2 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
8.3 Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
8.4 China
8.5 Japan
8.6 South Korea
8.7 Southeast Asia
8.8 India
8.9 Australia
9 Latin America
9.1 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
9.2 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
9.3 Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
9.4 Mexico
9.5 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size (2017-2028)
10.2 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022)
10.3 Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028)
10.4 Turkey
10.5 Saudi Arabia
10.6 UAE
11 Key Players Profiles
11.1 Ionis Pharmaceuticals, Inc
11.1.1 Ionis Pharmaceuticals, Inc Company Detail
11.1.2 Ionis Pharmaceuticals, Inc Business Overview
11.1.3 Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.1.4 Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.1.5 Ionis Pharmaceuticals, Inc Recent Development
11.2 Sarpeta Therapeutics Inc.
11.2.1 Sarpeta Therapeutics Inc. Company Detail
11.2.2 Sarpeta Therapeutics Inc. Business Overview
11.2.3 Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.2.4 Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.2.5 Sarpeta Therapeutics Inc. Recent Development
11.3 Biogen Inc
11.3.1 Biogen Inc Company Detail
11.3.2 Biogen Inc Business Overview
11.3.3 Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.3.4 Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.3.5 Biogen Inc Recent Development
11.4 Alnylam Pharmaceuticals, Inc
11.4.1 Alnylam Pharmaceuticals, Inc Company Detail
11.4.2 Alnylam Pharmaceuticals, Inc Business Overview
11.4.3 Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.4.4 Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.4.5 Alnylam Pharmaceuticals, Inc Recent Development
11.5 Antisense Therapeutics Limited
11.5.1 Antisense Therapeutics Limited Company Detail
11.5.2 Antisense Therapeutics Limited Business Overview
11.5.3 Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.5.4 Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.5.5 Antisense Therapeutics Limited Recent Development
11.6 Arrowhead Pharmaceuticals Inc.
11.6.1 Arrowhead Pharmaceuticals Inc. Company Detail
11.6.2 Arrowhead Pharmaceuticals Inc. Business Overview
11.6.3 Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.6.4 Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.6.5 Arrowhead Pharmaceuticals Inc. Recent Development
11.7 Enzon Pharmaceuticals, Inc.
11.7.1 Enzon Pharmaceuticals, Inc. Company Detail
11.7.2 Enzon Pharmaceuticals, Inc. Business Overview
11.7.3 Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.7.4 Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.7.5 Enzon Pharmaceuticals, Inc. Recent Development
11.8 Bio-Path Holdings, Inc.
11.8.1 Bio-Path Holdings, Inc. Company Detail
11.8.2 Bio-Path Holdings, Inc. Business Overview
11.8.3 Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.8.4 Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.8.5 Bio-Path Holdings, Inc. Recent Development
11.9 GlaxoSmithKline PLC
11.9.1 GlaxoSmithKline PLC Company Detail
11.9.2 GlaxoSmithKline PLC Business Overview
11.9.3 GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.9.4 GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.9.5 GlaxoSmithKline PLC Recent Development
11.10 Geron Corporation (Geron)
11.10.1 Geron Corporation (Geron) Company Detail
11.10.2 Geron Corporation (Geron) Business Overview
11.10.3 Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Introduction
11.10.4 Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
11.10.5 Geron Corporation (Geron) Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth Rate by Type (US$ Million): 2017 VS 2021 VS 2028
Table 2. Key Players of Pulmonary Delivery
Table 3. Key Players of Intravenous Injections
Table 4. Key Players of Intradermal Injections
Table 5. Key Players of Intraperitoneal Injections
Table 6. Key Players of Topical Delivery
Table 7. Key Players of Others
Table 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size Growth by Application (US$ Million): 2017 VS 2021 VS 2028
Table 9. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (US$ Million): 2017 VS 2021 VS 2028
Table 10. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 11. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2017-2022)
Table 12. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Region (2023-2028) & (US$ Million)
Table 13. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2023-2028)
Table 14. Antisense Oligonucleotide (ASO) Therapeutics Market Trends
Table 15. Antisense Oligonucleotide (ASO) Therapeutics Market Drivers
Table 16. Antisense Oligonucleotide (ASO) Therapeutics Market Challenges
Table 17. Antisense Oligonucleotide (ASO) Therapeutics Market Restraints
Table 18. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue by Players (2017-2022) & (US$ Million)
Table 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players (2017-2022)
Table 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2021)
Table 21. Ranking of Global Top Antisense Oligonucleotide (ASO) Therapeutics Companies by Revenue (US$ Million) in 2021
Table 22. Global 5 Largest Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue (CR5 and HHI) & (2017-2022)
Table 23. Key Players Headquarters and Area Served
Table 24. Key Players Antisense Oligonucleotide (ASO) Therapeutics Product Solution and Service
Table 25. Date of Enter into Antisense Oligonucleotide (ASO) Therapeutics Market
Table 26. Mergers & Acquisitions, Expansion Plans
Table 27. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Type (2017-2022) & (US$ Million)
Table 28. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2017-2022)
Table 29. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Type (2023-2028) & (US$ Million)
Table 30. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Type (2023-2028)
Table 31. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size by Application (2017-2022) & (US$ Million)
Table 32. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2017-2022)
Table 33. Global Antisense Oligonucleotide (ASO) Therapeutics Forecasted Market Size by Application (2023-2028) & (US$ Million)
Table 34. Global Antisense Oligonucleotide (ASO) Therapeutics Revenue Market Share by Application (2023-2028)
Table 35. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 36. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 37. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 38. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 39. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2017-2022) & (US$ Million)
Table 40. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size by Region (2023-2028) & (US$ Million)
Table 41. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 42. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 43. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2017-2022) & (US$ Million)
Table 44. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size by Country (2023-2028) & (US$ Million)
Table 45. Ionis Pharmaceuticals, Inc Company Detail
Table 46. Ionis Pharmaceuticals, Inc Business Overview
Table 47. Ionis Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 48. Ionis Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 49. Ionis Pharmaceuticals, Inc Recent Development
Table 50. Sarpeta Therapeutics Inc. Company Detail
Table 51. Sarpeta Therapeutics Inc. Business Overview
Table 52. Sarpeta Therapeutics Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 53. Sarpeta Therapeutics Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 54. Sarpeta Therapeutics Inc. Recent Development
Table 55. Biogen Inc Company Detail
Table 56. Biogen Inc Business Overview
Table 57. Biogen Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 58. Biogen Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 59. Biogen Inc Recent Development
Table 60. Alnylam Pharmaceuticals, Inc Company Detail
Table 61. Alnylam Pharmaceuticals, Inc Business Overview
Table 62. Alnylam Pharmaceuticals, Inc Antisense Oligonucleotide (ASO) Therapeutics Product
Table 63. Alnylam Pharmaceuticals, Inc Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 64. Alnylam Pharmaceuticals, Inc Recent Development
Table 65. Antisense Therapeutics Limited Company Detail
Table 66. Antisense Therapeutics Limited Business Overview
Table 67. Antisense Therapeutics Limited Antisense Oligonucleotide (ASO) Therapeutics Product
Table 68. Antisense Therapeutics Limited Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 69. Antisense Therapeutics Limited Recent Development
Table 70. Arrowhead Pharmaceuticals Inc. Company Detail
Table 71. Arrowhead Pharmaceuticals Inc. Business Overview
Table 72. Arrowhead Pharmaceuticals Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 73. Arrowhead Pharmaceuticals Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 74. Arrowhead Pharmaceuticals Inc. Recent Development
Table 75. Enzon Pharmaceuticals, Inc. Company Detail
Table 76. Enzon Pharmaceuticals, Inc. Business Overview
Table 77. Enzon Pharmaceuticals, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 78. Enzon Pharmaceuticals, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 79. Enzon Pharmaceuticals, Inc. Recent Development
Table 80. Bio-Path Holdings, Inc. Company Detail
Table 81. Bio-Path Holdings, Inc. Business Overview
Table 82. Bio-Path Holdings, Inc. Antisense Oligonucleotide (ASO) Therapeutics Product
Table 83. Bio-Path Holdings, Inc. Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 84. Bio-Path Holdings, Inc. Recent Development
Table 85. GlaxoSmithKline PLC Company Detail
Table 86. GlaxoSmithKline PLC Business Overview
Table 87. GlaxoSmithKline PLC Antisense Oligonucleotide (ASO) Therapeutics Product
Table 88. GlaxoSmithKline PLC Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 89. GlaxoSmithKline PLC Recent Development
Table 90. Geron Corporation (Geron) Company Detail
Table 91. Geron Corporation (Geron) Business Overview
Table 92. Geron Corporation (Geron) Antisense Oligonucleotide (ASO) Therapeutics Product
Table 93. Geron Corporation (Geron) Revenue in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022) & (US$ Million)
Table 94. Geron Corporation (Geron) Recent Development
Table 95. Research Programs/Design for This Report
Table 96. Key Data Information from Secondary Sources
Table 97. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Type: 2021 VS 2028
Figure 2. Pulmonary Delivery Features
Figure 3. Intravenous Injections Features
Figure 4. Intradermal Injections Features
Figure 5. Intraperitoneal Injections Features
Figure 6. Topical Delivery Features
Figure 7. Others Features
Figure 8. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Application in 2021 & 2028
Figure 9. Genetic Disorders Case Studies
Figure 10. Neurological Disorders Case Studies
Figure 11. Oncological Disorders Case Studies
Figure 12. Metabolic Disorders Case Studies
Figure 13. Ophthalmic Disorders Case Studies
Figure 14. Others Case Studies
Figure 15. Antisense Oligonucleotide (ASO) Therapeutics Report Years Considered
Figure 16. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size (US$ Million), Year-over-Year: 2017-2028
Figure 17. Global Antisense Oligonucleotide (ASO) Therapeutics Market Size, (US$ Million), 2017 VS 2021 VS 2028
Figure 18. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region: 2021 VS 2028
Figure 19. Global Antisense Oligonucleotide (ASO) Therapeutics Market Share by Players in 2021
Figure 20. Global Top Antisense Oligonucleotide (ASO) Therapeutics Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antisense Oligonucleotide (ASO) Therapeutics as of 2021)
Figure 21. The Top 10 and 5 Players Market Share by Antisense Oligonucleotide (ASO) Therapeutics Revenue in 2021
Figure 22. North America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 23. North America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2017-2028)
Figure 24. United States Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 25. Canada Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 26. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 27. Europe Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2017-2028)
Figure 28. Germany Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 29. France Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 30. U.K. Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 31. Italy Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 32. Russia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 33. Nordic Countries Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 34. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 35. Asia-Pacific Antisense Oligonucleotide (ASO) Therapeutics Market Share by Region (2017-2028)
Figure 36. China Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 37. Japan Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 38. South Korea Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 39. Southeast Asia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 40. India Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 41. Australia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 42. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 43. Latin America Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2017-2028)
Figure 44. Mexico Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 45. Brazil Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 46. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 47. Middle East & Africa Antisense Oligonucleotide (ASO) Therapeutics Market Share by Country (2017-2028)
Figure 48. Turkey Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 49. Saudi Arabia Antisense Oligonucleotide (ASO) Therapeutics Market Size YoY Growth (2017-2028) & (US$ Million)
Figure 50. Ionis Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 51. Sarpeta Therapeutics Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 52. Biogen Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 53. Alnylam Pharmaceuticals, Inc Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 54. Antisense Therapeutics Limited Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 55. Arrowhead Pharmaceuticals Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 56. Enzon Pharmaceuticals, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 57. Bio-Path Holdings, Inc. Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 58. GlaxoSmithKline PLC Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 59. Geron Corporation (Geron) Revenue Growth Rate in Antisense Oligonucleotide (ASO) Therapeutics Business (2017-2022)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
